All News

RheumNow Podcast square

RheumNow Podcast – Listener Questions (3.12.2021)

d Jack Cush, MD

Dr Jack Cush reviews the news, Journal reports, CDC guidelines and viewer questions from the last week on RheumNow.com

Read Article
Vaccine2.jpg (keep)

Low Anaphylaxis Risk with COVID mRNA Vaccines

d Jack Cush, MD

JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals. 

Read Article
COVID.virus_.corona.jpg (keep)

COVID-19-Related Deaths in Rheumatic Disease Patients

d Jack Cush, MD

There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.

Read Article
COVID vaccine vials

Comparison of Three Coronavirus Vaccines

d Jack Cush, MD

On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available.  We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth. 

Read Article
vaccination.jpg

CDC: Interim Guidance for COVID Vaccinated People

d Jack Cush, MD

Among 330 million Americans, roughly 32.1 million have been fully vaccinated and 61.1 million have received at least one dose of a COVID-19 vaccine (as of March 8th).

Read Article
Intraarticular Steroids in OA - They Dont work & Not Safe https://t.co/fB9SDFMVgf https://t.co/kk2VauefAe

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 45 studies, ∼175 000 individuals shows a significant association between pain and socioeconomic status (SES).Chronic pain was higher with low SES (OR 1.32) and medium SES level (OR 1.16) https://t.co/0MM0V1WUhi

Links:

Dr. John Cush RheumNow ( View Tweet)

Population claims based study of RA patients shows improvement in the 10-year risk of acute myocardial infarction over time (same as the general population). Nevertheless, RA pts have a 21 % higher risk of AMI than the matched general population https://t.co/zfsJftR9ZA

Links:

Dr. John Cush RheumNow ( View Tweet)

Free read on the 20 year history, immunology and targeting of interleukin-17 (IL-17) Great article by Professor Pierre Miossec https://t.co/69acTuPWZZ

Links:

Dr. John Cush RheumNow ( View Tweet)

We are just about one week out. Have you registered to attend? We have a robust schedule planned with digital access to all content and downloads. https://t.co/Woxi4Ri0O5 https://t.co/ADll6r8dFu

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Notalgia? Get a Clue - to the Dx of FM https://t.co/LRC7e8PPla https://t.co/K4pkWq39OC

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians. Sign up to attend virtually or in-person today. https://t.co/LJ3qClHTKh https://t.co/K3YgfFZhpa

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Ms. RA Can Multiple Sclerosis and RA Coexist? What Drugs can be used? https://t.co/PYFQI7vn3M

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of US National Inpatient Sample (2000‐2014). In #RA pts, there was a signif decline in annual rate of hospitalizations (76per million in 2000 to 30 per million 2014) & Hosp mortality (0.70% to 0.41%); but a signif incr in hosp for arthroplasty https://t.co/kkpmdKzEhQ

Links:

Dr. John Cush RheumNow ( View Tweet)

75 RA pts on MTX >3 yrs had FIBROSCANS done to assess their value. 12 pts (16%) had Fibroscan ≥ 7.1 kPa, 3 patients w/ severe liver stiffness (9.5 to 12.5 kPa) & 1 w/ cirrhosis range scores (> 12.5 kPa). No Bx were done; LFTs were not predictive https://t.co/Pi1h1nF0Uq

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: CDC: Interim Guidance for COVID Vaccinated People https://t.co/3GZDCVF0hv https://t.co/qyQyajjqM8

Links:

Dr. John Cush RheumNow ( View Tweet)
2020 Year in Review - Top Publications in SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to medical experts discuss their latest insights in spondyloarthritis and Still’s disease. View Now: https://t.co/rxTAwQNalx https://t.co/bmjrEdkf89

Links:

Dr. John Cush RheumNow ( View Tweet)
Matched cohort study f142 Takayasu arteritis pts - incidence 0.8 per million/Yr. TAK had increased in All‐cause mortality (adj HR 1.88 ;1.29–2.76), ischemic heart dz, CVA, TIA, CVD, PVD - but not HTN, CHF or DM. Only ~50% were on statins or anti-Plt Rx https://t.co/rgNqkha6sq

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish registry looked at odds of achieving remission with either Triple DMARD (347 MSH) or biologic Rx (1155) - more pts on biologics achieved remission at 1 yr (OR 1.79;1.18‐2.72) and 2 yrs (OR 1.92;1.21‐3.06). https://t.co/1MwhDbNxbf

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of 8416 pts w/ Kawasaki disease (KD) shows older and younger children differ. <10% were under 6 mos, 78%) were 6 mos-4yrs; 11% 5 to 9 yrs. Younger KD had more incomplete KD, coronary aneurysms, while older had more delayed diagnoses, more fever https://t.co/NkSmfg38ru

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×